Introduction
Under the impression of the overearth nuclear weapon tests (1954) (1955) (1956) (1957) (1958) (1959) (1960) (1961) (1962) (1963) , resulting in a hemi sphere wide contamination of the food chain with the radionuclides 134Cs and 137Cs, the benefit of oral administered hexacyanoferrate(II) com pounds (HCF) as antidote against radiocaesium incorporation in animals was demonstrated by several authors [1] [2] [3] [4] [5] [6] . However, the efficacy of dif ferent HCF compounds and dosages in compari son remained obscure (Table I) , and no admitted treatment procedure for the inhibition of radiocae sium absorption in humans and domestic animals Reprint requests to Dr. B. Dresow.
Verlag der Zeitschrift für Naturforschung, D-7400 Tübingen 0341 -0382/90 0600-0676 $01.30/0 was available as a result of these former studies. Some of the earlier contradictory results may have been caused by the fact that i) insufficiently puri fied and badly characterized compounds were used in most cases, and ii) the comparison of dif ferent compounds was influenced by overdosing the oral HCF (Table I) .
The nuclear reactor accident in Chernobyl (1986) has stimulated the discussion on the risks of environmental radioactive contamination to man and animals and the use of HCF as potential coun termeasure against radiocaesium absorption [7] [8] [9] [10] ,
In a previous in vitro study, it was demonstrated that the sorption capacity for caesium of some transition metal hexacyanoferrates(II) (Cu, Ni, Co, Zn) was twice as high as that of the more common iron hexacyanoferrates ("soluble" (KFeHCF) or "insoluble" (FeHCF) Prussian blue) [9] . More recently, manganese oxide was de scribed as a new compound for binding of cobalt and caesium isotopes in vitro [11] .
The aim of the present study in rats was to find out the most effective compound for inhibiting intestinal radiocaesium absorption in vivo and to establish an appropriate treatment procedure against incorporation of 137 134Cs from contami- 
mals were fasted 24 h prior and 6 h after oral ap plication in cages equipped with grid floors to minimize coprophagy. Hexacyanoferrates(II) in 0.5 ml water and tracer doses l34CsCl (0.3-0.8 jiCi) in 0.5 ml water were administered separately through a gastric tube, control animals received 134CsCl only. The 134Cs whole body activity, measured immediately after radiocaesium application in the center of a 4 rc-geometry whole body radioactivity detector with organic liquid scintillator for humans in the energy range of 500-1800 keV was taken as 100% reference value [12] [13] . After oral administration of the test compounds, the rats were placed in met abolic cages for 7 days to collect urine and faeces separately. The 134Cs whole body retention was measured again 7 days after 134Cs application by whole body counting. 134Cs-activity in urine and faeces of rats was measured in the whole body counter described above.
Results and Discussion

Effect o f the time o f HCF-administration on radiocaesium absorption
At various time intervals and with different se quence, 5 mg of KFeHCF and carrier free 134CsCl were administered separately through a gastric nated food in humans and domestic animals in the case of severe nuclear accident.
Materials and Methods 134CsCl (12.49 |iCi/(ig Cs) was obtained from Amersham International, England. Chemicals of analytical grade were obtained from E. Merck, Darmstadt (F.R.G.). Colloidal "soluble" and "in soluble" hexacyanoferrates(II) of Fe3+ , Co2+, Cu2+, Zn2+ and N i2+ were prepared as described previously [9] . The crude products were exhaus tively dialyzed against distilled water, concentrat ed in vacuum and dried by lyophilization. Ammonium-ferric(III)-hexacyanoferrate(II) ("GieseSalt", containing 30-35% ammonium chloride) was purchased from Riedel de Haen, Seelze (F.R.G.). Manganese oxide was prepared accord ing to Mikhail and Misak [11] , In vitro 134Cs-sorption capacity was measured as described [9] .
Animals
Female Wistar rats (260-280 g) were obtained from Wiga (Hannover, F.R.G.) and fed a standard rat diet (Altromin 1324, Altromin, Lage F.R.G.). Rats were housed in polyethylene cages with stain less steel wire tops or in metabolic cages (polyeth ylene cages with stainless steel grid floors). Ani tube to 5 fasted rats and the l34Cs absorption was calculated from the measured whole body reten tion after 7 days. Tracer amounts of orally admin istered radiocaesium were absorbed very quickly (Table II) . HCF application 30 min after 134CsCl ingestion exhibited only a small inhibitory effect on enteral caesium absorption compared to the control group receiving no HCF. Even an applica tion 2 min after the radiocaesium administration was still leading to a distinct 134Cs absorption in rats. For this small amount of HCF (5 mg), opti mal inhibition results were obtained by application of the hexacyanoferrate together or a few minutes before loading with radiocaesium. Table II 
Efficacy o f different H C F in rats
In a pilot experiment, 5 mg amounts of the dif ferent hexacyanoferrate(II) compounds were ad ministered to 8-10 rats by gastric intubation 2 min before oral loading with carrier-free 134CsCl. As judged by the 134Cs whole body retention after 7 days (Table III, Fig. 1) , K H C F had no signifi cant effect on the caesium absorption. The efficacy of KZnH CF and KCuH CF was only small in comparison, although these compounds showed a high caesium sorption capacity in vitro [9] . This difference might be caused by the much shorter contact time between these compounds and radio caesium in the intestinal tract compared to the in vitro experiments.
A distinct reduction of enteral radiocaesium ab sorption was observed by FeHCF, but 5 mg of KFeHCF, KN iH CF, KCoHCF, and N H 4FeHCF resulted in an almost complete blockade of the ra diocaesium absorption. Differences in efficacy be tween these four compounds could not be derived from this experiment because of the too high 5 mg HCF dose. This is in contrast to other authors (Table I) , who could set up an order of efficacy even with much higher HCF doses.
The caesium sorption effect of hexacyanoferrates(II) in the gastroenteral tract becomes ob vious by regarding the 134Cs-excretion in urine and faeces during 7 days after oral loading with 134CsCl (Table III) . In the control group (receiving no HCF), only 10% of the administered 134Cs-activity was found in the faeces, whereas 134Cs-application combined with oral HCF treatment leads with the best compounds to an almost complete (>98% ) faecal excretion of the label. Obviously, there was found a good negative correlation between 134Cs whole body retention and the excretion of 134Cs- Table III . Accumulated faecal and urinary excretion, whole body retention of l34Cs in rats (n = 9-10; in % o f oral dose after 7 days; mean ± SD). 5 mg o f H C F compounds were administered though a gastric tube 2 m in before oral 134CsCl-loading. Fig. 1 . Prevention o f intestinal radiocaesium ab sorption in rats. 5 mg o f H C F compounds were administered through a gastric tube 2 min before oral 134Cs-loading (carrier free l34CsCl, 0.3-0.8 (iCi). ,34Cs whole body retention was meas ured 7 days after oral application.
HCFcompound
activity in faeces within 7 days after administra tion (Table III) . For the comparison of the most effective com pounds (KFeHCF, N H 4FeHCF, KNiHCF, and KCoHCF) the H CF dose had to be reduced con siderably since a tracer dose of 134Cs was used. The administration of only 0.5 mg HCF 2 min before oral loading with carrier free 134CsCl still showed an inhibiting effect (5.2-2.8% average 134Cs-W BR) on the intestinal radiocaesium absorption. KFeHCF and N H 4FeHCF were effective to the same extent, whereas the inhibition effect of K N iH C F and K C oH C F was somewhat smaller (Fig. 2) . were administered through a gastric tube 2 min before oral l34Cs-loading (carrier free l34CsCl, 0.3-0.8 nCi). 134Cs whole body retention was measured 7 days after oral application.
As a result of this study at low H CF doses of 0.1 and 0.5 mg, the colloidal KFeHCF and N H 4FeHCF have to be considered as the most ef ficient antidotes for inhibiting the absorption of tracer doses of radiocaesium in rats. Higher doses of 5 mg HCF are required for obtaining the same inhibitory effects with FeHCF, K C oH C F and KN iHCF. This is in contrast to former studies of Seletskaya [6] or Giese [4] but can be compared to some extent with the results of Nigrovic [2] , despite this author used 50 mg doses of HCF, which, as our data clearly show, was overdosed.
After the Chernobyl accident, Giese, based on his study in rats 1971 [4] , suggested N H 4FeHCF (Giese-Salt, Riedel de Haen, F.R.G.) to be the most effective compound as antidote against radiocae sium absorption and for promoting the decorpora tion of already absorbed radiocaesium in domestic animals [8] . As shown in Fig. 2 , the commercial preparation (administered dose: 0.75 mg N H 4FeHCF, because of its known content of 30-35% ammonium chloride) was somewhat less effective as compared to the purified (non-commercial) N H 4FeHCF and KFeHCF-preparations, used in this study. An equal potency of purified KFeHCF and N H 4FeHCF for in vivo radiocae sium elimination is demonstrated in Table IV. As shown previously, only small amounts of fer ric and ferrous iron, as well as of cyanide are re leased and absorbed from oral doses of 59Fe and 14CN labelled KFe[Fe(CN)6] in piglets, rats and man [10, 14, 15] . This indicates that soluble Prus sian blue can be used without reservation and therefore must be considered as the most valuable antidote for the inhibition of Cs-absorption and decorporation of already absorbed radiocaesium. For medical use in man a separation of low molec ular by-products in crude commercial prepara tions is recommendable. More recently, the capability of manganese ox ide for the binding of radiocaesium isotopes in vi tro was demonstrated by Mikhail and Mizak [11] . However, in comparison with HCF compounds, we found a much lower caesium sorption capacity for M n 0 2 (water, 0.07 mmol Cs+ /g M nO,; artifi cial duodenal juice pH 6.8, 0.03 mmol/g; artificial gastric juice pH 1.2, 0.005 mmol/g) as compared to KFeHCF (about 1.0 mmol Cs+ /g KFeHCF). In addition, oral administered M n 0 2 (5 or 10 mg/ rat), showed no significant inhibiting effect on the absorption of carrier free ,34Cs (Table IV) . There fore, this compound is not suitable as antidote against intestinal radiocaesium absorption.
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